Cargando…

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

BACKGROUND: Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy. Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a major mechanism of action for the mAb trastuzumab. Conflicting results still...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petricevic, Branka, Laengle, Johannes, Singer, Josef, Sachet, Monika, Fazekas, Judit, Steger, Guenther, Bartsch, Rupert, Jensen-Jarolim, Erika, Bergmann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029549/ https://www.ncbi.nlm.nih.gov/pubmed/24330813 http://dx.doi.org/10.1186/1479-5876-11-307

Ejemplares similares

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Trastuzumab in the management of early and advanced stage breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2007)

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
por: Hudelist, G, et al.
Publicado: (2003)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Translating clinical trials from human to veterinary oncology and back
por: Fürdös, Irene, et al.
Publicado: (2015)

Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine
por: Fazekas, Judit, et al.
Publicado: (2016)

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
por: Milano, Francesca, et al.
Publicado: (2010)

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
por: Bartsch, Rupert, et al.
Publicado: (2006)

Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474
por: Fazekas, Judit, et al.
Publicado: (2017)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Hemocyte-Mediated Phagocytosis in Crustaceans
por: Liu, Shan, et al.
Publicado: (2020)

Dynamics of phagocytosis mediated by phosphatidylserine
por: Vorselen, Daan
Publicado: (2022)

Neu1 Is Released From Activated Microglia, Stimulating Microglial Phagocytosis and Sensitizing Neurons to Glutamate
por: Allendorf, David H., et al.
Publicado: (2022)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
por: Lewis Phillips, Gail, et al.
Publicado: (2021)

Neutrophil-Mediated Phagocytosis of Staphylococcus aureus
por: van Kessel, Kok P. M., et al.
Publicado: (2014)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Crosstalk of carcinoembryonic antigen and transforming growth factor-β via their receptors: comparing human and canine cancer
por: Jensen-Jarolim, Erika, et al.
Publicado: (2015)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice
por: Singer, Josef, et al.
Publicado: (2019)

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
por: Tsao, Li-Chung, et al.
Publicado: (2022)

In Vitro Macrophage-Mediated Phagocytosis Assay of Brain Tumors
por: Gardner, Madison, et al.
Publicado: (2020)

Enhanced Biomechanically Mediated “Phagocytosis” in Detached Tumor Cells
por: Goldstein, Yoel, et al.
Publicado: (2021)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial
por: Thallinger, Christiane, et al.
Publicado: (2016)

Mechanism of phagocytosis in dictyostelium discoideum: phagocytosis is mediated by different recognition sites as disclosed by mutants with altered phagocytotic properties
por: Vogel, G, et al.
Publicado: (1980)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors
Publicado: (1987)

Dendritic Cell-Mediated Phagocytosis but Not Immune Activation Is Enhanced by Plasmin
por: Borg, Rachael J., et al.
Publicado: (2015)

Roles of Microglial Phagocytosis and Inflammatory Mediators in the Pathophysiology of Sleep Disorders
por: Nadjar, Agnes, et al.
Publicado: (2017)

Brucella Phagocytosis Mediated by Pathogen-Host Interactions and Their Intracellular Survival
por: Huy, Tran X. N., et al.
Publicado: (2022)

Protrudin-mediated ER-endosome contact sites promote phagocytosis
por: Elfmark, Liv Anker, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nekfr25jkifd35chloav1bfpmm